Assembly Biosciences (ASMB) Cash & Current Investments (2010 - 2026)

Assembly Biosciences' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $226.6 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 148.94% year-over-year to $226.6 million; the TTM figure through Mar 2026 stood at $226.6 million (up 148.94% YoY), while the FY2025 annual figure was $248.1 million, up 121.37% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $226.6 million, down from $248.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $248.1 million in Q4 2025, with the low at $46.2 million in Q3 2023.
• The 5-year median for Cash & Current Investments is $109.2 million (2024), against an average of $120.7 million.
• The sharpest annual moves came in 2023 and 2026: Cash & Current Investments tumbled 57.47% in 2023, then surged 148.94% in 2026.
• Assembly Biosciences' Cash & Current Investments stood at $91.6 million in 2022, then surged by 42.18% to $130.2 million in 2023, then decreased by 13.95% to $112.1 million in 2024, then soared by 121.37% to $248.1 million in 2025, then fell by 8.67% to $226.6 million in 2026.
• Business Quant data shows ASMB's Cash & Current Investments at $226.6 million in Q1 2026, $248.1 million in Q4 2025, and $232.6 million in Q3 2025.